Urology Calculators

7-item questionnaire for lower urinary tract symptoms (LUTS) in BPH. Guides treatment decisions.

PSA Density = PSA / Prostate Volume (from TRUS). Helps differentiate benign BPH from prostate cancer.

Clinical risk stratification for renal/ureteric stone recurrence to guide metabolic workup and prevention.

EORTC-based risk stratification for non-muscle-invasive bladder cancer (NMIBC) recurrence and progression.

8-item validated questionnaire for diagnosis and monitoring of overactive bladder (OAB).

International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification for testicular germ cell tumours.

Mehran risk score for contrast-induced acute kidney injury (CI-AKI) after contrast exposure.

Pathological grading of prostate cancer. Modern reporting uses Grade Groups 1–5 (from Gleason sum 6 to 10). Guides treatment decision from active surveillance to radical therapy.

Testicular Workup for Ischaemia and Suspected Torsion (TWIST) score to guide immediate scrotal exploration vs USS in suspected testicular torsion.

Risk stratification for localised/locally advanced prostate cancer using PSA, Gleason grade group, and clinical stage to guide treatment planning.

Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence, metastasis, and cancer-specific death after prostatectomy. Score 0–2 = low risk; 3–5 = intermediate; 6–10 = high risk.

Calculates PSA velocity and doubling time for men with prostate cancer or rising PSA. PSADT <10 months after prostatectomy suggests systemic progression. Requires ≥2 PSA measurements.

Stratifies prostate cancer risk into low, intermediate, and high categories based on PSA, Gleason score, and clinical T stage. Widely used to guide initial treatment decisions.

Standardised scoring of renal tumour anatomy for surgical planning. Predicts operative complexity and guides decision between partial and radical nephrectomy.

Assesses lower urinary tract symptom (LUTS) severity in BPH. Guides watchful waiting vs medical vs surgical management.

Calculates PSA velocity (rate of PSA rise per year) and PSA density. PSA velocity >0.75 ng/mL/year or PSA density >0.15 ng/mL/mL suggests cancer risk.

Estimates spontaneous stone passage rate based on stone size and location. Guides conservative vs interventional management (SWL, URS, PCNL).

Estimates expected bladder capacity by age. Used in urodynamics and to assess functional bladder capacity.

Identifies risk factors for renal stone recurrence to guide metabolic evaluation and preventive treatment.

Predicts stone-free rate after percutaneous nephrolithotomy (PCNL) based on patient and stone characteristics.

Predicts probability of testicular torsion to guide immediate surgery vs scrotal USS. High score = immediate exploration without USS delay.

International Consultation on Incontinence Questionnaire (ICIQ-UI SF) scores urinary incontinence frequency, amount, and impact. Score 0-21.

5-item self-report of erectile function over past 6 months (Rosen 1999). Each item 1–5, total 5–25. Lower = worse. Validated screening for ED.

Stratifies localised prostate cancer recurrence risk after definitive treatment (D'Amico 1998). Combines PSA, Gleason and clinical T-stage. Underpins NICE NG131 treatment recommendations.